Bio-Sourcing has developed a unique, sustainable and profitable platform for the production of a new generation of biotherapeutics, in particular monoclonal antibodies.
Bio-Sourcing has raised €13M across 1 funding round from 1 investor, most recently a Grant round in Sep 2024. Based in Brussels, Belgium; active in Healthtech. Data as of 6 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-09-24 | Grant | €13M |
| European Innovation Council (EIC) Accelerator Programme |
| View deal → |
